{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:30:40Z","timestamp":1765758640906,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA016672","P01 CA124787"],"award-info":[{"award-number":["P30CA016672","P01 CA124787"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00520-021-06110-2","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T12:03:06Z","timestamp":1617278586000},"page":"6099-6107","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Minocycline for symptom reduction in patients with multiple myeloma during maintenance therapy: a phase II placebo-controlled randomized trial"],"prefix":"10.1007","volume":"29","author":[{"given":"Xin Shelley","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuling","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tito R.","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Araceli","family":"Garcia-Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsun Hsuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cobi","family":"Heijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles S.","family":"Cleeland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"issue":"19","key":"6110_CR1","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L, Garderet L, Decaux O, Leyvraz S, Vekemans M-C, Voillat L, Michallet M, Pegourie B, Dumontet C, Roussel M, Leleu X, Mathiot C, Payen C, Avet-Loiseau H, Harousseau J-L (2012) Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 366(19):1782\u20131791. https:\/\/doi.org\/10.1056\/NEJMoa1114138","journal-title":"N Engl J Med"},{"issue":"19","key":"6110_CR2","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C (2012) Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 366(19):1770\u20131781. https:\/\/doi.org\/10.1056\/NEJMoa1114083","journal-title":"N Engl J Med"},{"issue":"5","key":"6110_CR3","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3109\/10428194.2014.956313","volume":"56","author":"XS Wang","year":"2015","unstructured":"Wang XS, Shi Q, Williams LA, Shah ND, Mendoza TR, Cohen EN, Reuben JM, Cleeland CS, Orlowski RZ (2015) Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma. Leuk Lymphoma 56(5):1335\u20131341. https:\/\/doi.org\/10.3109\/10428194.2014.956313","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"6110_CR4","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1158\/1078-0432.Ccr-13-2442","volume":"20","author":"XS Wang","year":"2014","unstructured":"Wang XS, Shi Q, Shah ND, Heijnen CJ, Cohen EN, Reuben JM, Orlowski RZ, Qazilbash MH, Johnson VE, Williams LA, Mendoza TR, Cleeland CS (2014) Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation. Clin Cancer Res 20(5):1366\u20131374. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-2442","journal-title":"Clin Cancer Res"},{"issue":"1","key":"6110_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1517\/14740338.2011.619975","volume":"11","author":"A Palumbo","year":"2012","unstructured":"Palumbo A, Freeman J, Weiss L, Fenaux P (2012) The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes. Expert Opin Drug Saf 11(1):107\u2013120. https:\/\/doi.org\/10.1517\/14740338.2011.619975","journal-title":"Expert Opin Drug Saf"},{"issue":"7","key":"6110_CR6","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1007\/s00520-018-4137-x","volume":"26","author":"F Sparano","year":"2018","unstructured":"Sparano F, Cavo M, Niscola P, Caravita T, Efficace F (2018) Patient-reported outcomes in relapsed\/refractory multiple myeloma: a systematic review. Support Care Cancer 26(7):2075\u20132090. https:\/\/doi.org\/10.1007\/s00520-018-4137-x","journal-title":"Support Care Cancer"},{"issue":"22","key":"6110_CR7","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1182\/blood.V128.22.4507.4507","volume":"128","author":"KR Kelly","year":"2016","unstructured":"Kelly KR, Wu K, Tsao-Wei D, Groshen S, Triche TJ Jr, Mohrbacher A, Chang G, Fernando D, Siddiqi IN, Coffey M, Gill G, Lee A, Carew JS, Nawrocki ST (2016) Oncolytic reovirus immune priming: a phase 1b study of reolysin with bortezomib and dexamethasone in patients with relapsed\/refractory multiple myeloma. Blood 128(22):4507\u20134507. https:\/\/doi.org\/10.1182\/blood.V128.22.4507.4507","journal-title":"Blood"},{"issue":"4","key":"6110_CR8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.soncn.2016.09.001","volume":"32","author":"A Barsevick","year":"2016","unstructured":"Barsevick A (2016) Symptom clusters. Semin Oncol Nurs 32(4):333. https:\/\/doi.org\/10.1016\/j.soncn.2016.09.001","journal-title":"Semin Oncol Nurs"},{"issue":"12","key":"6110_CR9","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1002\/sim.4780101207","volume":"10","author":"M Schumacher","year":"1991","unstructured":"Schumacher M, Olschewski M, Schulgen G (1991) Assessment of quality of life in clinical trials. Stat Med 10(12):1915\u20131930. https:\/\/doi.org\/10.1002\/sim.4780101207","journal-title":"Stat Med"},{"issue":"11","key":"6110_CR10","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1016\/s1470-2045(14)70263-3","volume":"15","author":"CI Diakos","year":"2014","unstructured":"Diakos CI, Charles KA, McMillan DC, Clarke SJ (2014) Cancer-related inflammation and treatment effectiveness. Lancet Oncol 15(11):e493\u2013e503. https:\/\/doi.org\/10.1016\/s1470-2045(14)70263-3","journal-title":"Lancet Oncol"},{"issue":"6","key":"6110_CR11","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1200\/jco.2007.10.7805","volume":"26","author":"AH Miller","year":"2008","unstructured":"Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR (2008) Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol 26(6):971\u2013982. https:\/\/doi.org\/10.1200\/jco.2007.10.7805","journal-title":"J Clin Oncol"},{"key":"6110_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainresbull.2015.10.009","volume":"120","author":"J Majidi","year":"2016","unstructured":"Majidi J, Kosari-Nasab M, Salari A-A (2016) Developmental minocycline treatment reverses the effects of neonatal immune activation on anxiety- and depression-like behaviors, hippocampal inflammation, and HPA axis activity in adult mice. Brain Res Bull 120:1\u201313. https:\/\/doi.org\/10.1016\/j.brainresbull.2015.10.009","journal-title":"Brain Res Bull"},{"key":"6110_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.brainresbull.2018.08.015","volume":"143","author":"H-Y Liu","year":"2018","unstructured":"Liu H-Y, Yue J, Hu L-N, Cheng L-F, Wang X-S, Wang X-J, Feng B (2018) Chronic minocycline treatment reduces the anxiety-like behaviors induced by repeated restraint stress through modulating neuroinflammation. Brain Res Bull 143:19\u201326. https:\/\/doi.org\/10.1016\/j.brainresbull.2018.08.015","journal-title":"Brain Res Bull"},{"issue":"5","key":"6110_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8","journal-title":"J Chronic Dis"},{"key":"6110_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1756-8722-6-13","volume":"6","author":"D Jones","year":"2013","unstructured":"Jones D, Vichaya EG, Wang XS, Williams LA, Shah ND, Thomas SK, Johnson VE, Champlin RE, Cleeland CS, Mendoza TR (2013) Validation of the M. D. Anderson Symptom Inventory multiple myeloma module. J Hematol Oncol 6:13. https:\/\/doi.org\/10.1186\/1756-8722-6-13","journal-title":"J Hematol Oncol"},{"issue":"7","key":"6110_CR16","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1002\/1097-0142(20001001)89:7<1634::aid-cncr29>3.0.co;2-v","volume":"89","author":"CS Cleeland","year":"2000","unstructured":"Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, Engstrom MC (2000) Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 89(7):1634\u20131646. https:\/\/doi.org\/10.1002\/1097-0142(20001001)89:7<1634::aid-cncr29>3.0.co;2-v","journal-title":"Cancer"},{"issue":"10","key":"6110_CR17","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/hed.20602","volume":"29","author":"DI Rosenthal","year":"2007","unstructured":"Rosenthal DI, Mendoza TR, Chambers MS, Asper JA, Gning I, Kies MS, Weber RS, Lewin JS, Garden AS, Ang KK, X SW, Cleeland CS (2007) Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module. Head Neck 29(10):923\u2013931. https:\/\/doi.org\/10.1002\/hed.20602","journal-title":"Head Neck"},{"issue":"6","key":"6110_CR18","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.bbi.2010.03.009","volume":"24","author":"XS Wang","year":"2010","unstructured":"Wang XS, Shi Q, Williams LA, Mao L, Cleeland CS, Komaki RR, Mobley GM, Liao Z (2010) Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun 24(6):968\u2013974. https:\/\/doi.org\/10.1016\/j.bbi.2010.03.009","journal-title":"Brain Behav Immun"},{"issue":"5","key":"6110_CR19","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.bbi.2011.12.007","volume":"26","author":"XS Wang","year":"2012","unstructured":"Wang XS, Williams LA, Krishnan S, Liao Z, Liu P, Mao L, Shi Q, Mobley GM, Woodruff JF, Cleeland CS (2012) Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain Behav Immun 26(5):699\u2013705. https:\/\/doi.org\/10.1016\/j.bbi.2011.12.007","journal-title":"Brain Behav Immun"},{"issue":"4","key":"6110_CR20","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jpainsymman.2019.06.018","volume":"58","author":"XS Wang","year":"2019","unstructured":"Wang XS, Shi Q, Bhadkamkar NA, Cleeland CS, Garcia-Gonzalez A, Aguilar JR, Heijnen C, Eng C (2019) Minocycline for symptom reduction during oxaliplatin-based Chemotherapy for colorectal cancer: a phase II randomized clinical trial. J Pain Symptom Manag 58(4):662\u2013671. https:\/\/doi.org\/10.1016\/j.jpainsymman.2019.06.018","journal-title":"J Pain Symptom Manag"},{"issue":"7","key":"6110_CR21","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1002\/cncr.23299","volume":"112","author":"E Campagnaro","year":"2008","unstructured":"Campagnaro E, Saliba R, Giralt S, Roden L, Mendoza F, Aleman A, Cleeland C, Weber D, Brown J, Anderson KO (2008) Symptom burden after autologous stem cell transplantation for multiple myeloma. Cancer 112(7):1617\u20131624. https:\/\/doi.org\/10.1002\/cncr.23299","journal-title":"Cancer"},{"key":"6110_CR22","doi-asserted-by":"publisher","unstructured":"Gunn GB, Mendoza TR, Garden AS, Wang XS, Shi Q, Morrison WH, Frank SJ, Phan J, Fuller CD, Chambers MS, Hanna EY, Lu C, Rosenthal DI, Cleeland CS (2019) Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial. Support Care Cancer. https:\/\/doi.org\/10.1007\/s00520-019-04791-4","DOI":"10.1007\/s00520-019-04791-4"},{"issue":"1","key":"6110_CR23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ijrobp.2019.10.010","volume":"106","author":"XS Wang","year":"2020","unstructured":"Wang XS, Shi Q, Mendoza T, Lin S, Chang JY, Bokhari RH, Lin HK, Garcia-Gonzalez A, Kamal M, Cleeland CS, Liao Z (2020) Minocycline reduces chemoradiation-related symptom burden in patients with non-small cell lung cancer: a phase 2 randomized trial. Int J Radiat Oncol Biol Phys 106(1):100\u2013107. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.10.010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6110_CR24","doi-asserted-by":"publisher","unstructured":"Kamal M, Wang XS, Shi Q, Mendoza T, Garcia-Gonzalez A, Bokhari RH, Cleeland CS, Fogelman DR (2020) A Randomized, placebo-controlled, double-blind study of minocycline for reducing the symptom burden experienced by patients with advanced pancreatic cancer. J Pain Symptom Manag. https:\/\/doi.org\/10.1016\/j.jpainsymman.2020.01.007","DOI":"10.1016\/j.jpainsymman.2020.01.007"},{"issue":"5","key":"6110_CR25","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jpainsymman.2012.11.003","volume":"46","author":"E Boland","year":"2013","unstructured":"Boland E, Eiser C, Ezaydi Y, Greenfield DM, Ahmedzai SH, Snowden JA (2013) Living with advanced but stable multiple myeloma: a study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life. J Pain Symptom Manag 46(5):671\u2013680. https:\/\/doi.org\/10.1016\/j.jpainsymman.2012.11.003","journal-title":"J Pain Symptom Manag"},{"issue":"4","key":"6110_CR26","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1600-0609.2012.01831.x","volume":"89","author":"F Mols","year":"2012","unstructured":"Mols F, Oerlemans S, Vos AH, Koster A, Verelst S, Sonneveld P, van de Poll-Franse LV (2012) Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry. Eur J Haematol 89(4):311\u2013319. https:\/\/doi.org\/10.1111\/j.1600-0609.2012.01831.x","journal-title":"Eur J Haematol"},{"issue":"1","key":"6110_CR27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/pon.1710","volume":"20","author":"A Molassiotis","year":"2011","unstructured":"Molassiotis A, Wilson B, Blair S, Howe T, Cavet J (2011) Unmet supportive care needs, psychological well-being and quality of life in patients living with multiple myeloma and their partners. Psycho-oncology 20(1):88\u201397. https:\/\/doi.org\/10.1002\/pon.1710","journal-title":"Psycho-oncology"},{"issue":"3","key":"6110_CR28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1385\/mo:19:3:133","volume":"19","author":"V Jurisic","year":"2002","unstructured":"Jurisic V, Colovic M (2002) Correlation of sera TNF-alpha with percentage of bone marrow plasma cells, LDH, beta2-microglobulin, and clinical stage in multiple myeloma. Med Oncol 19(3):133\u2013139. https:\/\/doi.org\/10.1385\/mo:19:3:133","journal-title":"Med Oncol"},{"issue":"9","key":"6110_CR29","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","volume":"100","author":"PG Richardson","year":"2002","unstructured":"Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J, Anderson KC (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100(9):3063\u20133067. https:\/\/doi.org\/10.1182\/blood-2002-03-0996","journal-title":"Blood"},{"issue":"10","key":"6110_CR30","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.bbmt.2013.05.011","volume":"19","author":"M Mohty","year":"2013","unstructured":"Mohty M, Brissot E, Savani BN, Gaugler B (2013) Effects of bortezomib on the immune system: a focus on immune regulation. Biol Blood Marrow Transplant 19(10):1416\u20131420. https:\/\/doi.org\/10.1016\/j.bbmt.2013.05.011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"6110_CR31","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1615\/CritRevImmunol.v26.i6.20","volume":"26","author":"A Nencioni","year":"2006","unstructured":"Nencioni A, Grunebach F, Patrone F, Ballestrero A, Brossart P (2006) The proteasome and its inhibitors in immune regulation and immune disorders. Crit Rev Immunol 26(6):487\u2013498","journal-title":"Crit Rev Immunol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06110-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-021-06110-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06110-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T09:20:17Z","timestamp":1630488017000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-021-06110-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["6110"],"URL":"https:\/\/doi.org\/10.1007\/s00520-021-06110-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2021,4,1]]},"assertion":[{"value":"13 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"The study was approved by the IRB committee at MD Anderson Cancer Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was signed by all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All patients gave consent with respect to the publication of the data collected as a part of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing financial interests to declare. RZO declares laboratory research funding from BioTheryX and clinical research funding from CARsgen Therapeutics, Celgene, Exelixis, Janssen Biotech, Sanofi-Aventis, Takeda Pharmaceuticals North America, Inc. Also, RZO has served on advisory boards for Amgen, Inc., Bristol-Myers Squibb, Celgene, EcoR1 Capital LLC, Forma Therapeutics, Genzyme, GSK Biologicals, Ionis Pharmaceuticals, Inc., Janssen Biotech, Juno Therapeutics, Kite Pharma, Legend Biotech USA, Molecular Partners, Regeneron Pharmaceuticals, Inc., Sanofi-Aventis, Servier, and Takeda Pharmaceuticals North America, Inc., and as a consultant for STATinMED Research. Finally, RZO is a Founder of Asylia Therapeutics, Inc., with associated patents and an equity interest, though this technology does not bear on the current manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}